← Back to headlines
Merck's KEYTRUDA Receives FDA Priority Review for Bladder Cancer
Merck & Co., Inc. (MRK) has been granted FDA Priority Review for its KEYTRUDA regimen in the treatment of muscle-invasive bladder cancer.
23 Apr, 08:40 — 23 Apr, 08:40
Sources
Showing 1 of 1 sources
